124 related articles for article (PubMed ID: 12591991)
21. [Cancer antigen CA 125 in ovarian cancer].
Debniak J; Stukan M; Pietrzak-Stukan M; Klasa-Mazurkiewicz D
Ginekol Pol; 2003 Sep; 74(9):701-9. PubMed ID: 14674111
[TBL] [Abstract][Full Text] [Related]
22. Can rumors cause cancer?
Jones J
J Natl Cancer Inst; 2000 Sep; 92(18):1469-71. PubMed ID: 10995800
[No Abstract] [Full Text] [Related]
23. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
25. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
26. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer.
Wu X; Li D; Liu L; Liu B; Liang H; Yang B
Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
Rzymski P; Woźniak J; Opala T; Sajdak S; Drews K
Ginekol Pol; 2002 Nov; 73(11):1090-5. PubMed ID: 12722404
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
29. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
30. Advances in the early detection of ovarian cancer: How to hear the whispers early.
Cesario S
Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
[No Abstract] [Full Text] [Related]
31. Beyond evidence: reappraising use of CA-125 as post-therapy surveillance for ovarian cancer.
Harnett P; Kerridge IH; Jordens CF; Hobbs K; Mason C; Morrell BM
Med J Aust; 2012 Apr; 196(7):440-1. PubMed ID: 22509867
[No Abstract] [Full Text] [Related]
32. Differential diagnosis of adnexal masses: sequential use of the risk of malignancy index and HistoScanning, a novel computer-aided diagnostic tool.
Vaes E; Manchanda R; Autier P; Nir R; Nir D; Bleiberg H; Robert A; Menon U
Ultrasound Obstet Gynecol; 2012 Jan; 39(1):91-8. PubMed ID: 21695741
[TBL] [Abstract][Full Text] [Related]
33. Ovarian fibroma with marked ascites and elevated serum levels of CA-125 in a young girl.
Sugiyama A; Urushihara N; Fukumoto K; Fukuzawa H; Nagae H; Watanabe K; Mitsunaga M; Hasegawa S; Koyama M
J Pediatr Surg; 2011 May; 46(5):1001-4. PubMed ID: 21616270
[TBL] [Abstract][Full Text] [Related]
34. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
[TBL] [Abstract][Full Text] [Related]
36. Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
Ann Intern Med; 2012 Dec; 157(12):I-56. PubMed ID: 23362519
[No Abstract] [Full Text] [Related]
37. [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
Grabiec M; Nowicki P; Walentowicz M; Greźlikowska U; Mierzwa T; Chmielewska W
Ginekol Pol; 2005 May; 76(5):371-6. PubMed ID: 16145856
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
39. Personalizing ovarian cancer screening.
Goozner M
J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
[No Abstract] [Full Text] [Related]
40. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
Burch D; Metcalfe S; Gallagher G; al-Azzawi F; Wheeler T
Eur J Gynaecol Oncol; 1994; 15(5):352-8. PubMed ID: 7828604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]